GlassScriptPhysician profile
Nicole E Baker
NPI 1235340332
$7,426.27
in general payments reported to CMS, 2019-2025
34 companies · $74.99 in 2025
The $74.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $825 · 2021: $1,470 · 2022: $1,330 · 2023: $1,789 · 2024: $1,272 · 2025: $74.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,051.63 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $773.60 | 2019-2024 | |
| Novo Nordisk INC | $545.68 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $495.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $493.19 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $329.95 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $262.66 | 2020-2021 | |
| Lilly USA, LLC | $191.86 | 2019-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $172.83 | 2019-2023 | Belsomra |
| Amgen INC. | $156.24 | 2020-2025 | Repatha, Otezla, Otezla |
| Genzyme Corporation | $124.99 | 2023 | |
| Glaxosmithkline, LLC. | $105.53 | 2020-2024 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.62 | 2019-2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $58.05 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $55.62 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.50 | 2019-2020 | |
| Astellas Pharma US INC | $45.44 | 2019 | |
| Eisai INC. | $44.16 | 2020-2021 | |
| Exact Sciences Corporation | $34.97 | 2023-2024 | Cologuard Collection Kit |
| Nevro Corp. | $34.48 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $32.89 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $32.69 | 2022-2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $30.74 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.42 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.53 | 2022 | |
| Aimmune Therapeutics, INC. | $21.94 | 2025 | Zenpep |
| Abbott Laboratories | $19.32 | 2023 | Freestyle Libre 3 |
| Emd Serono, INC. | $18.41 | 2019 | |
| Daiichi Sankyo INC. | $17.84 | 2023 | Injectafer |
| Endo Pharmaceuticals INC. | $17.74 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.03 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.